Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; 23 of the 62 sources its claims cite were checked for support.
Abstract
Preclinical studies demonstrate that rapid acting antidepressants, including ketamine require stimulation of mTORC1 signaling. This pathway is regulated by neuronal activity, endocrine and metabolic signals, notably the amino acid leucine, which activates mTORC1 signaling via binding to the upstream regulator sestrin. Here, we examined the antidepressant actions of NV-5138, a novel highly selective small molecule modulator of sestrin that penetrates the blood brain barrier. The results demonstrate that a single dose of NV-5138 produced rapid and long-lasting antidepressant effects, and rapidly reversed anhedonia caused by chronic stress exposure. The antidepressant actions of NV-5138 required BDNF release as the behavioral responses are blocked by infusion of a BDNF neutralizing antibody into the medial prefrontal cortex (mPFC) or in mice with a knock-in of a BDNF polymorphism that blocks activity dependent BDNF release. NV-5138 administration also rapidly increased synapse number and function in the mPFC, and reversed the synaptic deficits caused by chronic stress. Together, the results demonstrate that NV-5138 produced rapid synaptic and antidepressant behavioral responses via activation of the mTORC1 pathway and BDNF signaling, indicating that pharmacological modulation of sestrin is a novel approach for development of rapid acting antidepressants.
Overview
CoChat Summary
TL;DR
NV-5138, a brain-penetrant sestrin modulator, produced rapid and long-lasting antidepressant-like behavioral effects and reversed chronic stress–induced synaptic deficits in rodents. These effects required mTORC1 signaling and BDNF and were accompanied by increased synapse number and function in the medial prefrontal cortex.
Key findings
- A single oral dose of NV-5138 at 160 mg/kg, but not 40 or 80 mg/kg, significantly reduced immobility in the FST and latency to feed in the NSFT; leucine (160 mg/kg) had no effect.
- Single-dose NV-5138 and ketamine (10 mg/kg) produced antidepressant-like effects lasting up to 7 days in the FST, while repeated low-dose NV-5138 (80 mg/kg daily for 7 days) also significantly reduced immobility and latency to feed.
- NV-5138 rapidly reversed chronic unpredictable stress–induced decreases in sucrose preference and increased NSFT latency, and reversed CUS-induced reductions in mPFC GluR1 and PSD95.
- The behavioral actions of NV-5138 were blocked by intra-mPFC rapamycin or BDNF-neutralizing antibody and were absent in BDNF Val/Met and Met/Met knockin mice; NV-5138 also increased hypocretin-induced EPSC frequency, spine density, and synaptic proteins in mPFC.
Methods
- Male Sprague-Dawley rats (250–260 g; 120–140 g for CUS) and BDNF Val66Met knockin mice (8–12 weeks) were used; NV-5138 was given orally, ketamine intraperitoneally, and rapamycin, BDNF nAb, or IgG were infused into the mPFC.
- Behavioral assays included FST, NSFT, FUST, locomotor activity, home-cage feeding, and sucrose preference; CUS consisted of 21 days of variable stressors (13 stressors, 2 per day).
- Mechanistic measures included Western blots of synaptosomal PFC proteins, whole-cell patch recordings of layer V pyramidal neurons, and confocal spine analysis; data were analyzed with ANOVA/Tukey tests or Student’s t tests, with significance at P ≤ 0.05.
Limitations
- The authors state that the CUS conclusion is tempered because they did not test the influence of NV-5138 on mTORC1 signaling in CUS-exposed rats.
- The authors note that NBQX pretreatment did not block the FST effect and only partially, nonsignificantly blocked the NSFT effect, but state that higher or additional NBQX doses could reveal an AMPA receptor requirement.
- The authors state that further studies are needed to assess side effects in rodents and primates, including whether mTORC1 activation could influence tumor growth; the text also makes evident that the findings are preclinical and most behavioral studies used male rats.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
11 Valid · 0 Not valid · 21 Not checked · 75 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Preclinical studies demonstrate that rapid-acting antidepressants, including ketamine, require stimulation of mTORC1 signaling.”
What the sources say
- Supportedcites [7] matched to “mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists” (2010) source
The passages on ketamine’s behavioral effects and Ro 25-6981 (passages 4 and 5, labeled Abstract in our copy) report rapid antidepressant-like effects in preclinical tests that were blocked by rapamycin. The paper also reports activation of mTOR signaling by both drugs, supporting the attributed requirement for this pathway in the agents studied. (LLM, conf=0.90)
- Partly supportedcites [8] matched to “Glutamate N-methyl-D-aspartate Receptor Antagonists Rapidly Reverse Behavioral and Synaptic Deficits Caused by Chronic Stress Exposure” (2011) sourceExperimental — accuracy not yet measured
The Results report that rapamycin blocked ketamine’s reversal of behavioral deficits in chronically stressed rats, supporting a requirement for mTOR signaling in that preclinical model. The paper describes a rapamycin-sensitive mTOR pathway but does not identify it specifically as mTORC1 or establish this requirement for rapid-acting antidepressants generally. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“recent studies demonstrate that a single, subanesthetic dose of ketamine produces rapid (within hours) and long-lasting (7 to 10 days) antidepressant effects even in patients who have failed to respond to traditional antidepressants and are considered treatment resistant (5, 6).”
What the sources say
- Partly supportedcites [5] matched to “Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics” (2015) sourceExperimental — accuracy not yet measured
The INTRODUCTION and the section 'THE RAPID ANTIDEPRESSANT EFFECTS OF KETAMINE' support most of the claim: a single low (subanesthetic) IV dose produced effects within 4 h in severely treatment-resistant/refractory depressed patients, replicated across five placebo-controlled studies, with effects persisting for two weeks or longer in some patients. However, the specific duration the citing sentence attributes — 'long-lasting (7 to 10 days)' — is not what our copy states: the controlled-study figure given is 'sustained for 3–7 days' with a 40–60% response rate at 24 h, and the longer durations are described only as occurring 'in some patients'. The 7–10 day magnitude is therefore an extrapolation beyond the source's stated figures. (LLM, conf=0.70)
- Not checked yetcites [6] matched to “Antidepressant effects of ketamine in depressed patients” (2000) source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As expected, a single dose of NV-5138 (160 mg/kg) rapidly increased levels of phospho-mTOR as well as the downstream targets, phospho-p70S6K1, and phospho-4EB-P1, in synaptosomal preparations of PFC (Figure 4, C-E), confirming recent studies (22).”
What the sources say
- Partly supportedcites [22] Sengupta S, et al. Discovery of NV-5138, the first selective Brain mTORC1 activator. Sci Rep . 2019;9(1):4107. https://doi.org/10.1038/s41598-019-40693-5 sourceExperimental — accuracy not yet measured
The Results section (Pharmacokinetics and Pharmacodynamics; page not available) reports increased phosphorylated S6 in PFC synaptoneurosomes one hour after a 160 mg/kg dose, supporting rapid mTORC1 activation. It does not report increased phospho-mTOR, phospho-p70S6K1, or phospho-4EB-P1 in those preparations; those specific measurements are not supported by our copy. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The BDNF Met polymorphism blocks the processing and activity-dependent release of mature BDNF (33).”
What the sources say
- Partly supportedcites [33] Chen ZY, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science . 2006;314(5796):140-143. https://doi.org/10.1126/science.1129663 sourceExperimental — accuracy not yet measured
The passage labeled Abstract reports an approximately 30% reduction in activity-dependent BDNF release, not a block. It also says neuronal studies suggest no defect in BDNFMet processing, although additional processing defects remain possible. The claim therefore overstates the release finding and is not supported on processing. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous studies demonstrate that infusion of rapamycin alone into the mPFC has no effect on these behaviors (7, 8, 10, 12).”
What the sources say
- Could not verifycites [7] matched to “mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists” (2010) sourceExperimental — accuracy not yet measured
The passage labeled Abstract describing Fig. 3D–E says that rapamycin infused into the medial PFC blocked ketamine’s behavioral effects in the forced swim and novelty-suppressed feeding tests. It does not report the behavioral effects of rapamycin infused alone; searches for that comparison found no passage addressing it. (LLM, conf=0.72)
- Partly supportedcites [8] matched to “Glutamate N-methyl-D-aspartate Receptor Antagonists Rapidly Reverse Behavioral and Synaptic Deficits Caused by Chronic Stress Exposure” (2011) sourceExperimental — accuracy not yet measured
The Results report that rapamycin alone had no effect in the sucrose preference or novelty-suppressed feeding tests in stressed rats. However, the Results and Materials and Methods specify infusion into the lateral ventricles (ICV), not into the mPFC; that location is unsupported by this paper. (LLM, conf=0.90)
- Supportedcites [10] matched to “Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2 R ,6 R )-hydroxynorketamine” (2019) source
The Fig. 4 caption (Materials and Methods; page not specified) reports that rapamycin infused into the mPFC alone had no effect on immobility time or latency to feed, the behaviors tested in the FST and NSFT. (LLM, conf=0.94)
- Partly supportedcites [12] matched to “Scopolamine Rapidly Increases Mammalian Target of Rapamycin Complex 1 Signaling, Synaptogenesis, and Antidepressant Behavioral Responses” (2013) sourceExperimental — accuracy not yet measured
The Results section reports that a previous study found no effect of rapamycin alone on immobility in the forced swim test. But it specifies an intracerebroventricular (i.c.v.) injection, not an infusion into the mPFC, and does not establish no effect on other behaviors. (LLM, conf=0.87)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
59 more claims · 2 with their cited sources checked
Create a free account to see all 107 claims and to verify the 39 references still open.
- It may state two separate claims as one. 29
- The quote only partly states this claim. 1
- Probably not a substantial claim. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“work from our group and others has shown that quantification of SV2A is similar to that of other markers of synaptic density in clinical samples and after drug challenge”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [71]
Experimental — accuracy not yet measuredIn the citing paper
“Work by Ron Duman, in collaboration with our group, demonstrated elevated synaptic protein expression, including SV2A, in the prefrontal cortex of rats 24-hours (time comparable to human peak antidepressant effects) after a single subanesthetic dose of ketamine (10 mg/kg)”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 5
“2-way ANOVA and Tukey's multiple comparison test.”
§ Results · p. 5
“1-way ANOVA ( B -D , F , G ) and Student's t test ( E ).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 4
“Figure 2. Single-dose NV-5183 produces long-lasting antidepressant effects, and repeated low-dose NV-5138 also produces antidepressant effects.”
§ Results · p. 4
“Three or seven days after NV-5138 (160 mg/kg) or ketamine (10 mg/kg) administration, the FST was conducted.”
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Self-citationNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Willner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737
Zoncu, R., Bar-Peled, L., Efeyan, A., Wang, S., Sancak, Y., & Sabatini, D. M. (2011) · Science · doi:10.1126/science.1207056 · Cited by 1,673
Willner, P. (2005) · Neuropsychobiology · doi:10.1159/000087097 · Cited by 1,605
Research works printed but not linked: 2
- 10.1002/(sici)1097-4644(20000501)77:2 · doi:10.1002/(sici)1097-4644(20000501)77:2
- Abdallah CG, Sanacora G, Duman RS, Krystal JH. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med . 2015;66:509-523. https://doi.org/10.1146/annurev-med-053013-062946 · DOI · Paper page
Cited by
mTOR at the nexus of nutrition, growth, ageing and disease
Liu, G. Y., & Sabatini, D. M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0199-y · Cited by 2,737
Goul, C., Peruzzo, R., & Zoncu, R. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00641-8 · Cited by 269
Ketamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01629-w · Cited by 262
“The role of mTOR in antidepressant action is also supported by evidence of antidepressant activity of a direct mTOR activator [126, 127].”
BackgroundThe stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders
Sanacora, G., Yan, Z., & Popoli, M. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00540-x · Cited by 197
Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine
Deyama, S., & Duman, R. S. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.172837 · Cited by 186
“, 2019) and NV-5138 (an mTORC1 activator; see above) (Kato et al., 2019).”
BackgroundInfluentialSelf-citationThe central moTOR of metabolism
Simcox, J., & Lamming, D. W. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.02.024 · Cited by 174
Sestrin prevents atrophy of disused and aging muscles by integrating anabolic and catabolic signals
Segalés, J., Perdiguero, E., Serrano, A. L., Sousa-Victor, P., Ortet, L., Jardí, M., Budanov, A. V., Garcia-Prat, L., Sandri, M., Thomson, D. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13832-9 · Cited by 153
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · CNS Drugs · doi:10.1007/s40263-021-00816-x · Cited by 142
“Animal models subsequently found that NV-5138 had rapid antidepressant effects [120, 121].”
BackgroundForkhead Box O Signaling Pathway in Skeletal Muscle Atrophy
Chen, K., Gao, P., Li, Z., Dai, A., Yang, M. W. O., Chen, S., Su, J., Deng, Z., & Li, L. (2022) · American Journal Of Pathology · doi:10.1016/j.ajpath.2022.09.003 · Cited by 135
The molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
Design of fast-onset antidepressant by dissociating SERT from nNOS in the DRN
Sun, N., Qin, Y., Chu, X., Xia, T., Du, Z., Zheng, L., Li, A., Meng, F. J., Zhang, Y., Zhang, J., et al. (2022) · Science · doi:10.1126/science.abo3566 · Cited by 128
Novel drug developmental strategies for treatment‐resistant depression
Borbély, É., Simon, M., Fuchs, E., Wiborg, O., Czéh, B., & Helyes, Z. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15753 · Cited by 106
“These findings suggest that direct activation of mTORC1 signalling might be effective for depression therapy (Hasegawa et al., 2019; Kato et al., 2019), but Phase I/II study (NCT03606395) results have not yet confirmed the beneficial effect in humans (Table 1).”
BackgroundInfluentialExaptive Evolution of Target of Rapamycin Signaling in Multicellular Eukaryotes
Brunkard, J. O. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.06.022 · Cited by 91
Imaging the effect of ketamine on synaptic density (SV2A) in the living brain
Holmes, S. E., Finnema, S. J., Naganawa, M., DellaGioia, N., Holden, D., Fowles, K., Davis, M., Ropchan, J., Emory, P., Ye, Y., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01465-2 · Cited by 78
“While animal studies show that ketamine induces increases in synaptic proteins and density [14, 40, 65], PET is generally not as sensitive as techniques such as Western blot analysis and two-photon microscopy [65], such that human PET imaging may not be capable of capturing the changes detected in animal studies.”
BackgroundSelf-citationKrystal, J. H., Kaye, A. P., Jefferson, S., Girgenti, M. J., Wilkinson, S. T., Sanacora, G., & Esterlis, I. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305772120 · Cited by 91
Neurobiology of the rapid-acting antidepressant effects of ketamine: impact and opportunities
Shinohara, R., Aghajanian, G. K., & Abdallah, C. G. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.12.006 · Cited by 54
Teotia, P., Van Hook, M. J., Fischer, D., & Ahmad, I. (2019) · Development · doi:10.1242/dev.178012 · Cited by 48
“Recently, a small molecule, NV-5138, has been shown to activate mTORC1 both in vivo and in vitro (Kato et al., 2019; Sengupta et al., 2019).”
BackgroundDeyama, S., & Kaneda, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109335 · Cited by 49
Jiang, C. S., Dileone, R., Pittenger, C., & Duman, R. S. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02796-0 · Cited by 92
“FST was conducted as previously described [30].”
InfluentialSelf-citationLuo, H., Wu, P., Cao, Y., Jin, M. J., Shen, T., Wang, J., Huang, J., Han, Q.-Q., He, J., Deng, S., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.02.005 · Cited by 50
Deus, L. A., Corrêa, H. D. L., Neves, R. V. P., Reis, A. L., Honorato, F. S., Silva, V. L., Souza, M. K., de Araújo, T. B., Alves, L. S. D. G., Sousa, C. V., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182111299 · Cited by 53
“Moreover, evidence shows that BDNF is associated with sestrins [17], a biological mediator of exercise benefits, which its release can be increased through RT in patients under hemodialysis treatment [18,19].”
BackgroundResultLu, X., Liu, H., Cai, Z., Hu, Z., Ye, M., Gu, Y., Wang, Y., Wang, D., Lu, Q., Shen, Z., et al. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2022.08.005 · Cited by 38
Nutrient sensing of mTORC1 signaling in cancer and aging
Jiang, C., Tan, X., Liu, N., Yan, P., Hou, T., & Wei, W. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.08.001 · Cited by 42
SESTRINs: Emerging Dynamic Stress-Sensors in Metabolic and Environmental Health
Ro, S., Fay, J., Cyuzuzo, C. I., Jang, Y., Lee, N., Song, H., & Harris, E. N. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.603421 · Cited by 37
“Recently, Navitor Pharmaceuticals developed Sestrin2-specific inhibitor, a leucine analog NV-5138, and try to treat the major depressive disorder (MDD) by activating mTORC1 in the brain (Hasegawa et al., 2019; Kato et al., 2019; Sengupta et al., 2019).”
BackgroundIs Adult Hippocampal Neurogenesis Really Relevant for the Treatment of Psychiatric Disorders?
Carli, M., Aringhieri, S., Kolachalam, S., Longoni, B., Grenno, G., Rossi, M., Gemignani, A., Fornai, F., Maggio, R., & Scarselli, M. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200818194948 · Cited by 34
“Moreover, the blood-brain barrier-permeable molecule NV-5138, which activates mTORC1, produces ketamine-like changes and antidepressant behavioral responses [94].”
BackgroundLuo, W., Xu, H., Xu, L., Jiang, W., Chen, C., Chang, Y., Liu, C., Tian, Z., Qiu, X., Xie, C., et al. (2022) · Glia · doi:10.1002/glia.24271 · Cited by 30
“NV-5138 is a novel synthetic analog of leucine that has sufficient brain penetrability to selectively bind sestrins to induce the activation of the mTORC1 pathway (Kato et al., 2019).”
BackgroundMethodLi, H., & Seugnet, L. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-02020 · Cited by 30
Chaki, S., & Watanabe, M. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109348 · Cited by 30
Hooshmandi, M., Sharma, V. K., Pérez, C. T., Sood, R., Simbriger, K., Wong, C., Lister, K. C., Guzmán, A. U., Bartley, T., Rocha, C., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.06.017 · Cited by 32
KATO, T. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109325 · Cited by 27
Self-citationDysregulation of mTOR signalling is a converging mechanism in lissencephaly
Zhang, C., Liang, D., Ercan‐Sencicek, A. G., Bulut, A. S., Cortés, J., Cheng, I. Q., Henegariu, O., Nishimura, S., Wang, X., Peksen, A. B., et al. (2025) · Nature · doi:10.1038/s41586-024-08341-9 · Cited by 23
Chen, F., Li, L., Huang, M., Wang, Y., Wang, L., Jin, F., Yang, L., Gao, M., Li, L., Wang, Y., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155452 · Cited by 25
Dysregulated translational control in brain disorders: from genes to behavior
Wiebe, S. A., Nagpal, A., & Sonenberg, N. (2020) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.05.005 · Cited by 24
“activation is required for the antidepressant effects of NV5138 [15].”
BackgroundMethodInfluentialBrain-derived neurotrophic factor (BDNF): a multifaceted marker in chronic kidney disease
Afşar, B., & Afşar, R. E. (2022) · Clinical and Experimental Nephrology · doi:10.1007/s10157-022-02268-z · Cited by 24
NV-5138 as a fast-acting antidepressant via direct activation of mTORC1 signaling
Hasegawa, Y., Zhu, X., & Kamiya, A. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129702 · Cited by 20
Tanuma, M., Kasai, A., Bando, K., Kotoku, N., Harada, K., Minoshima, M., Higashino, K., Kimishima, A., Arai, M., Ago, Y., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133348 · Cited by 21
“in the synaptic cleft by binding to SERT, especially in the medial prefrontal cortex, a brain region implicated in antidepressant effects (24).”
BackgroundCholewinski, T., Pereira, D., Moerland, M., & Jacobs, G. E. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211036814 · Cited by 20
Lucido, M. J., & Dunlop, B. W. (2025) · Brain Sciences · doi:10.3390/brainsci15020161 · Cited by 24
“It has demonstrated rapid antidepressant effects in a small clinical study [114] and is now in Phase 2.”
Peng, F., Fan, J., Ge, T., Liu, Q. Q., & Li, B. J. (2020) · Cell Proliferation · doi:10.1111/cpr.12804 · Cited by 20
Glycogen Synthase Kinase-3: A Focal Point for Advancing Pathogenic Inflammation in Depression
McCallum, R. T., & Perreault, M. L. (2021) · Cells · doi:10.3390/cells10092270 · Cited by 21
Deyama, S., Aoki, S., Sugie, R., Fukuda, H., Shuto, S., Minami, M., & Kaneda, K. (2023) · Neurotherapeutics · doi:10.1007/s13311-022-01337-1 · Cited by 19
“In contrast, NV-5138, an mTORC1 activator, produces rapid antidepressant-like effects in rodents [65].”
BackgroundSannino, S., Manuel, A. M., Shang, C., Wendell, S. G., Wipf, P., & Brodsky, J. L. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0843 · Cited by 22
Deyama, S., & Kaneda, K. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112844 · Cited by 18
Resolvins as potential candidates for the treatment of major depressive disorder
Deyama, S., Minami, M., & Kaneda, K. (2021) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2021.05.002 · Cited by 19
Vasiliu, O. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.884155 · Cited by 22
“The impact of NV-5138 on synaptic function and BDNF signaling is similar to ketamine, suggesting a shared mTORC1 signaling-mediated mechanism for their antidepressant effect (Kato et al., 2019).”
BackgroundInfluentialXiao, H., Zhang, Q., Zhong, P., Tang, G., Tao, L., Huang, Z., Guo, D., Liao, Y., Peng, Y., Wu, Z., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00381 · Cited by 15
Study on Antidepressant Effect and Mechanism of Crocin Mediated by the mTOR Signaling Pathway
Wang, Y., Zhou, S., Song, X., Ding, S., Wang, B., Wen, J., & Chen, C. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03668-z · Cited by 17
“Ketamine, for example, regulated the expression of postsynaptic density protein (PSD95) and Synapsin-1 by activating mTOR and BDNF signaling pathways in mPFC, instantaneously activating downstream 4e binding protein1 (4E-BP1) and p70S6K [10].”
BackgroundAsch, R. H., Abdallah, C. G., Carson, R. E., & Esterlis, I. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01913-3 · Cited by 13
A renaissance in targeting the PI3K/AKT/mTOR pathway
Conduit, S. E., Vasan, N., Brown, J. R., Perry, M. W. D., & Vanhaesebroeck, B. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01388-5 · Cited by 20
“The use of NV-5138 in the context of depression is based on the detection of reduced mTORC1 activity in the brain of patients with depression 299 .”
Khamsing, D., Lebrun, S., Fanget, I., Larochette, N., Tourain, C., de Sars, V., Brunstein, M., Oheim, M., Carrel, D., Darchen, F., et al. (2021) · Molecular Brain · doi:10.1186/s13041-021-00820-8 · Cited by 14
“Recently, a Sestrin modulator, NV-5138, has been shown to produce a similar rapid and long-lasting antidepressant effect also by improving mTORC1 activation and synaptic plasticity in a BDNFdependent manner [82].”
BackgroundDeyama, S., Sugie, R., Tabata, M., & Kaneda, K. (2023) · Nutritional Neuroscience · doi:10.1080/1028415x.2023.2254542 · Cited by 9
“It was conducted as previously described with slight modi fi cations [10, 21 – 24 , 30 ].”
BackgroundMethodMoraga‐Amaro, R., Guerrin, C. G. J., Nazario, L. R., Giacobbo, B. L., Dierckx, R., Stehberg, J., de Vries, E. F. J., & Doorduin, J. (2022) · Stress · doi:10.1080/10253890.2022.2045269 · Cited by 9
“Sucrose preference test (SPT) was used to determine changes in depressive-like behavior since it has been shown that this test was sensible enough to detect long-term changes after a single ketamine injection (Kato et al., 2019; Viana et al., 2021).”
MethodImplication of sestrin3 in epilepsy and its comorbidities
Lovisari, F., Roncon, P., Soukupovà, M., Paolone, G., Labasque, M., Ingusci, S., Falcicchia, C., Marino, P., Johnson, M. R., Rossetti, T., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa130 · Cited by 9
“developed already (Kato et al., 2019), suggesting that it”
Molecular Mechanisms of Depression: The Interplay Between Genes and Receptors
Oatu, A., Trifu, S. C., & Coman, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311325 · Cited by 10
“…that directly activates mTORC1 in the medial prefrontal cortex, reverses anhedonia for up to seven days after a single oral dose in rodents—an effect blocked by BDNF neutralisation [210]—further underscoring the centrality of BDNF-dependent plasticity pathways in rapid antidepressant responses.”
Translational control in neurovascular brain development
Chalkiadaki, K., Statoulla, E., Μάρκου, Μ., Bellou, S., Bagli, E., Fotsis, T., Murphy, C., & Gkogkas, C. G. (2021) · Royal Society Open Science · doi:10.1098/rsos.211088 · Cited by 6
Zhao, L., Yin, R., Zhang, K., Huang, J., Zheng, R., Zhu, Y., Li, G., Lei, N., Xiong, L., & Xie, Y. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05325-2 · Cited by 7
Activating protein kinases to treat diseases: Current understanding and future challenges
Jin, P., Liao, M., Liu, H., Huang, K., Fu, L., & Jin, X. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.12.004 · Cited by 7
“NV-5138, a novel dual activator of mammalian target of rapamycin complex 1 (mTORC1) and brain-derived neurotrophic factor (BDNF) signaling pathways, represents an innovative neural plasticity-targeting strategy for depression therapeutics 161 .”
InfluentialShin, J., Lee, J., Choi, J., Ahn, B.-T., Jang, S. C., You, S.-W., Koh, D.-Y., Maeng, S., & Cha, S.-Y. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/6897359 · Cited by 9
Resolvins as novel targets for rapid-acting antidepressants
Deyama, S. (2020) · Folia Pharmacologica Japonica · doi:10.1254/fpj.20044 · Cited by 5
Sestrins as Biomarkers of Cellular Stress and Human Disease
Haidurov, A., & Budanov, A. V. (2026) · Cells · doi:10.3390/cells15070651 · Cited by 4
Sestrins in Carcinogenesis—The Firefighters That Sometimes Stoke the Fire
Haidurov, A., & Budanov, A. V. (2025) · Cancers · doi:10.3390/cancers17091578 · Cited by 5
“NV-5138 demonstrated antidepressant effects in rodent models in an mTORC1-dependent manner [109].”
Understanding the Molecular Basis of Miller–Dieker Syndrome
Mahendran, G., & Brown, J. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157375 · Cited by 5
“NV-5138 crosses the blood–brain barrier and acts specifically in brain regions such as the prefrontal cortex [149].”
Chu, H., Sun, N., Tang, Q., Yu, X. L., Li, L., & Hong-sheng, C. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119960 · Cited by 4
Calvo, I. A., Sharma, S., Paulo, J. A., Gulka, A. O. D., Boeszoermenyi, A., Zhang, J., Lombana, J. M., Palmieri, C. M., Laviolette, L. A., Arthanari, H., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103338 · Cited by 3
Huntington’s disease phenotypes are improved via mTORC1 modulation by small molecule therapy
St-Cyr, S., Child, D. D., Giaime, E., Smith, A. R., Pascua, C. J., Hahm, S., Saiah, E., & Davidson, B. L. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273710 · Cited by 4
Self-citationLin, Z., He, L., Wang, J., Zhang, H., Yao, S., Guo, J., Zhang, X., Liang, T., & Bai, X. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108003 · Cited by 4
Targum, S. D., Sanacora, G., Formella, A. E., Ceresoli‐Borroni, G., & Owen, R. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.01.006 · Cited by 2
Zahid, M., Khan, A., Sawali, M. A., Mohamed, O. A., Gharaibeh, A. M., & Agouni, A. (2025) · Molecules · doi:10.3390/molecules30244791 · Cited by 1
“This complexity likely contributed to the recent clinical trial failure of NV-5138, a SESN2-targeting drug designed to activate mTORC1 for treating depression [7–9].”
How Sweet It Is: Small-Molecule Inhibitors of mTORC1 Glucose Sensing
Zhang, J., & Bar‐Peled, L. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.09.001 · Cited by 1
Nasser, A. F., Owen, J. R., Goméni, R., Kosheleff, A. R., Portelli, J., Adeojo, L., & Hughes, T. E. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.12.015 · Cited by 2
Bulky substrates of isoleucine 2-epimerase: α-Neopentylglycine and NV-5138
Sorbara, N. T., Black, A. K. A., & Bearne, S. L. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130160 · Cited by 1
Where is the Mechanistic Target of Rapamycin Signaling Pathway in Depression?
Lee, J. A. (2022) · Mood and Emotion · doi:10.35986/me.2022.20.2.23 · Cited by 1
Deyama, S. (2023) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.23-00111 · Cited by 2
Trejo, L. J., Rosipal, R., Moore, A., Lujan, B., Kosheleff, A. R., Ereshefsky, L., Owen, R., & Vlasuk, G. P. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/hu7ba · Cited by 1
Self-citationFaculty Opinions recommendation of mTOR at the nexus of nutrition, growth, ageing and disease.
Ferguson, S. M. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737205281.793574661
Les acides aminés branchés, un lien « essentiel » entre alimentation, horloge et sommeil ?
Seugnet, L. (2022) · Médecine du Sommeil · doi:10.1016/j.msom.2022.11.001
Ram, B. M., Shriwas, O., Xu, M., Chuang, K.-H., & Dai, C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.24.595838
SPG11 models reveal lysosomal calcium as a regulator of neural progenitor proliferationPreprint
Samaroo, D., Cauhapé, M., Bernachot, L., & Darios, F. D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.21.665525
Moore, M., Katsumi, Y., Iordan, A. D., Dolcos, S. M., & Dolcos, F. (2025) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780197677131.013.32
Djorovic, D. J., Ivanović, J., Jezdić, K., Sharmin, D., Aranđelović, J., Cook, J. M., & Savić, M. M. (2025) · Medicinska istrazivanja · doi:10.5937/medi0-57913
Khamsing, D., Lebrun, S., Fanget, I., Larochette, N., Tourain, C., de Sars, V., Brunstein, M., Oheim, M., Carrel, D., Darchen, F., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14955902
Khamsing, D., Lebrun, S., Fanget, I., Larochette, N., Tourain, C., de Sars, V., Brunstein, M., Oheim, M., Carrel, D., Darchen, F., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14955911
Khamsing, D., Lebrun, S., Fanget, I., Larochette, N., Tourain, C., de Sars, V., Brunstein, M., Oheim, M., Carrel, D., Darchen, F., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14955908
Khamsing, D., Lebrun, S., Fanget, I., Larochette, N., Tourain, C., de Sars, V., Brunstein, M., Oheim, M., Carrel, D., Darchen, F., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14955899
Brown, K. A., Morris, P. J., Thomas, C. J., & Gould, T. D. (2026) · Journal of Neuroscience · doi:10.1523/jneurosci.0958-25.2026 · Cited by 1
SPG11 models reveal lysosomal calcium regulation of neural progenitor proliferation
Samaroo, D., Cauhapé, M., Bernachot, L., Moulière, S., & Darios, F. D. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107423 · Cited by 1
Chang, S., Chen, W., Zhu, W., Liu, N., Wang, Y., Li, J. N., & Kang, J. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01739-7
Deyama, S., Ito-Shintai, K., Sugie, R., Tabata, M., Sakaguchi, H., & Kaneda, K. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124619
Metadata
- Authors
- Kato, T., Pothula, S., Liu, R.-J., Duman, C. H., Terwilliger, R., Vlasuk, G. P., Saiah, E., Hahm, S., & Duman, R. S.
- Affiliations
- Sumitomo Dainippon Pharma (Japan) (JP)
- Yale University (US)
- Corresponding author
- Duman, Ronald S.
- Venue
- Journal of Clinical Investigation
- Published
- 2019-05-20
- Volume
- 129
- Issue
- 6
- Pages
- 2542-2554
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6546461
- OpenAlex
- W2936807256
- Semantic Scholar
- 12f7e7e41f49a3362421ed722b77861aaed57af9
- Cited by
- 88
- References
- 50
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 7 · 2023: 8 · 2022: 18 · 2021: 16 · 2020: 14 · 2019: 4
- FWCI
- 8.05
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIMH, Navitor Pharmaceuticals Inc. (MH093897,MH105910)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- sestrins, mTORC1 signaling, rapid-acting antidepressants, antidepressant effects, brain-derived neurotrophic factor, chronic stress, anhedonia, medial prefrontal cortex, synapse number, synaptic deficits, leucine, blood-brain barrier, ketamine
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Animals, Antidepressive Agents, Behavior, Animal, Heat-Shock Proteins, Male, Synaptic Transmission, Rats, Sprague-Dawley, Mice, Knockout, Brain-Derived Neurotrophic Factor, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.